Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal (Q39820716)

14 September 2017

1 reference

title

Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal (English)

1 reference

14 September 2017

0 references

Nelson JD

1

1 reference

PubMed ID

3889252

14 September 2017

language of work or name

English

0 references

publication date

1 June 1985

1 reference

The Journal of Pediatrics

14 September 2017

1 reference

14 September 2017

106

1 reference

14 September 2017

6

1 reference

14 September 2017

1030-1034

1 reference

Use of selective media in bacteriological investigation of patients with chronic suppurative respiratory infection

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Sputum bacteriology in patients with cystic fibrosis in a Toronto hospital during 1970-1981

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Staphylococcus aureus empyema in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Cloxacillin absorption and disposition in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Clinical pharmacology of extended-spectrum penicillins in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2885%2980264-X

10.1016/S0022-3476(85)80264-X

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference

PubMed ID

3889252